AN2 Therapeutics, Inc. Deferred Offering Costs
AN2 Therapeutics, Inc. (ANTX) had Deferred Offering Costs of $0 as of 2023-12-31, per its 10-K filed 2024-03-29.
Discontinued › Balance Sheet › Assets › Assets, Current
us-gaap:DeferredOfferingCosts · last filed 2024-03-29
- 2023-12-31: Deferred Offering Costs $0.00.
- 2023-09-30: Deferred Offering Costs $0.00.
- 2023-08-15: Deferred Offering Costs $4.50M.
- 2023-06-30: Deferred Offering Costs $0.00.
| Period end | Deferred Offering Costs |
|---|---|
| 2023-12-31 | $0.00 10-K · filed 2024-03-29 |
| 2023-09-30 | $0.00 10-Q · filed 2023-11-09 |
| 2023-08-15 | $4.50M 10-K · filed 2024-03-29 |
| 2023-06-30 | $0.00 10-Q · filed 2023-08-10 |
| 2023-04-06 | $900.00K 10-K · filed 2024-03-29 |
| 2023-03-31 | $50.00K 10-Q · filed 2023-05-11 |
| 2022-12-31 | $0.00 10-K · filed 2024-03-29 |
| 2022-03-31 | $3.30M 10-Q · filed 2022-08-11 |
| 2022-03-24 | $3.30M 10-K · filed 2024-03-29 |
| 2021-12-31 | $1.70M 10-K · filed 2023-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 |